BACKGROUND: Two approaches to the procurement of recombinant Factor VIII products are used by health systems: (A) the most common approach where acquisition tenders are not carried out; (B) the approach tested in the UK in which procurement is based on tenders. The respective cost-effectiveness is not known. OBJECTIVE: To estimate the incremental cost-effectiveness ratio (ICER) for the comparison A vs B. METHODS: The analysis evaluated: (i) Factor VIII cost with/without tenders; (ii) inhibitor development caused by switching between products; (iii) clinical and economic consequences of inhibitors. Information on these items was obtained from a literature search. Because of the scarce evidence available on some items, our analysis considered the 'most favourable' scenario-that is, some extreme though reasonable assumptions were adopted that were intentionally biased towards improving the ICER of the no-tender option. RESULTS AND DISCUSSION: We estimated an ICER for A vs B of £486 409 (€657 139; £1=€1.351) per quality-adjusted life year (QALY). Since pharmacoeconomic thresholds are ∼£30 000 per QALY, our results indicate that the cost-effectiveness of acquisition strategies that avoid tenders is prohibitive. Because of the simplified nature of our analysis, this estimate is preliminary. CONCLUSIONS: The 'true' ICER of A vs B remains unknown, but its value is likely to be even worse than the unfavourable ICER of £486 409 (€657 139) per QALY.
BACKGROUND: Two approaches to the procurement of recombinant Factor VIII products are used by health systems: (A) the most common approach where acquisition tenders are not carried out; (B) the approach tested in the UK in which procurement is based on tenders. The respective cost-effectiveness is not known. OBJECTIVE: To estimate the incremental cost-effectiveness ratio (ICER) for the comparison A vs B. METHODS: The analysis evaluated: (i) Factor VIII cost with/without tenders; (ii) inhibitor development caused by switching between products; (iii) clinical and economic consequences of inhibitors. Information on these items was obtained from a literature search. Because of the scarce evidence available on some items, our analysis considered the 'most favourable' scenario-that is, some extreme though reasonable assumptions were adopted that were intentionally biased towards improving the ICER of the no-tender option. RESULTS AND DISCUSSION: We estimated an ICER for A vs B of £486 409 (€657 139; £1=€1.351) per quality-adjusted life year (QALY). Since pharmacoeconomic thresholds are ∼£30 000 per QALY, our results indicate that the cost-effectiveness of acquisition strategies that avoid tenders is prohibitive. Because of the simplified nature of our analysis, this estimate is preliminary. CONCLUSIONS: The 'true' ICER of A vs B remains unknown, but its value is likely to be even worse than the unfavourable ICER of £486 409 (€657 139) per QALY.
Entities:
Keywords:
DRUG PROCUREMENT; EPIDEMIOLOGY; HEALTH ECONOMICS; HEALTH SERVICES ADMINISTRATION & MANAGEMENT; PHARMACOECONOMICS
Authors: M V Ragni; O Ojeifo; J Feng; J Yan; K A Hill; S S Sommer; M N Trucco; D J Brambilla Journal: Haemophilia Date: 2009-06-26 Impact factor: 4.287
Authors: G Auerswald; M von Depka Prondzinski; B Ehlken; W Kreuz; K Kurnik; H Lenk; I Scharrer; W Schramm; R Zimmermann Journal: Haemophilia Date: 2004-09 Impact factor: 4.287
Authors: S C Darby; D M Keeling; R J D Spooner; S Wan Kan; P L F Giangrande; P W Collins; F G H Hill; C R M Hay Journal: J Thromb Haemost Date: 2004-07 Impact factor: 5.824